Breaking News Instant updates and real-time market news.

PEP

PepsiCo

$107.78

-1.78 (-1.62%)

, XLRN

Acceleron

$47.34

0.58 (1.24%)

09:09
07/10/18
07/10
09:09
07/10/18
09:09

On The Fly: Pre-market Movers

UP AFTER EARNINGS: PepsiCo (PEP), up 3%. ALSO HIGHER: Acceleron (XLRN), up 6% after the company and partner Celgene (CELG) announced that a phase 3 study of luspatercept achieved a highly statistically significant improvement in the primary endpoint of erythroid response... VIVUS (VVUS), up 19% after announcing preliminary results from a Phase 1 clinical study evaluating the pharmacokinetic profile of its VI-0106, a soft capsule formulation of tacrolimus for the treatment of pulmonary arterial hypertension. LOWER: iRobot (IRBT), down 4% after being downgraded to Market Perform from Outperform at Raymond James... Cactus (WHD), down 4% after filing to sell 10M shares of Class A common stock.

PEP

PepsiCo

$107.78

-1.78 (-1.62%)

XLRN

Acceleron

$47.34

0.58 (1.24%)

IRBT

iRobot

$80.91

0.02 (0.02%)

WHD

Cactus

$35.58

1.49 (4.37%)

CELG

Celgene

$83.86

1.42 (1.72%)

VVUS

VIVUS

$0.75

0.0163 (2.22%)

  • 10

    Jul

  • 26

    Jul

  • 20

    Aug

  • 04

    Sep

  • 07

    Sep

  • 12

    Jul

PEP PepsiCo
$107.78

-1.78 (-1.62%)

07/06/18
WELS
07/06/18
NO CHANGE
Target $107
WELS
Market Perform
Wells Fargo cautious on PepsiCo fundamentals into Q2 results
Wells Fargo analyst Bonnie Herzog is cautious on PepsiCo's fundamentals ahead of the company's Q2 earnings results on July 10. The analyst reduced her fiscal 2018 and 2019 estimates to reflect continued weakness in North American beverages, lower sales in Latin America following the May trucker strike in Brazil and incremental currency headwinds. However, despite these continued pressures, the market could react favorably to PepsiCo management providing more details on their ultimate plans for the Beverage business, Herzog tells investors in a pre-earnings research note titled "PEP: We're Not Feeling So Bubly About PEP's Q2 Fundamentals." The analyst keeps a Market Perform rating on PepsiCo with a $107 price target.
07/03/18
DBAB
07/03/18
DOWNGRADE
Target $116
DBAB
Hold
PepsiCo downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Stephen Powers downgraded PepsiCo to Hold with an unchanged price target of $116. The stock closed yesterday up 66c to $109.53. The analyst views the current valuation as a "bit bubbly." With at least 36 months of elevated investment, the stock's current risk/reward is fairly balanced, Powers tells investors in a research note.
07/03/18
07/03/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. United Continental (UAL), American Airlines (AAL), and Delta Airlines (DAL) downgraded to Hold from Buy at Deutsche Bank with analyst Michael Linenberg saying in a world of "heightened" macroeconomic and geopolitical risks, economically-sensitive, high beta stocks such as airlines typically underperform the broader market. 2. Belmond (BEL) downgraded to Underweight from Overweight at Barclays with analyst Felicia Hendrix citing an analysis of the company's progress on its growth targets announced back in June 2016. 3. PSEG (PEG) downgraded to Hold from Buy at Deutsche Bank with analyst Jonathan Arnold saying The Federal Energy Regulatory Commission order raised new questions over New Jersey zero-emission credits. 4. PepsiCo (PEP) downgraded to Hold from Buy at Deutsche Bank with analyst Stephen Powers viewing the current valuation as a "bit bubbly." 5. Watsco (WSO), Fastenal (FAST), and Grainger (GWW) downgraded to Neutral from Outperform at Baird with analyst David Manthey saying he thinks the cycle and individual company results could remain solid for quarters or years to come, but he believes the cycle is in its later stages, thereby elevating risks to gross margins, rising labor costs, and earnings deceleration in 2019. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/09/18
RBCM
07/09/18
NO CHANGE
Target $111
RBCM
Sector Perform
PepsiCo to remain constrained by troubled Beverage business, says RBC Capital
RBC Capital analyst Nik Modi previews Q2 results for PepsiCo, saying he expects the trends of troubled North America Beverage business and poor earnings quality that have been on display over the past few quarters to persist. Modi further warns that FX and cost increases will worsen in this quarter, while the operating environment becomes more uncertain because of the threat of trade wars. The analyst keeps his Sector Perform rating and $111 price target on PepsiCo.
XLRN Acceleron
$47.34

0.58 (1.24%)

07/10/18
HCWC
07/10/18
NO CHANGE
Target $74
HCWC
Buy
Acceleron price target raised to $74 from $69 at H.C. Wainwright
H.C. Wainwright analyst Edward White raised his price target for Acceleron Pharma to $74 citing the positive results from the Phase 3 Believe study of luspatercept in transfusion-dependent beta-thalassemia patients. The analyst expects sales in 2020 of $31M, growing to $260M in 2026. He keeps a Buy rating on Acceleron.
07/10/18
UBSW
07/10/18
NO CHANGE
Target $62
UBSW
Buy
Acceleron price target raised to $62 from $57 at UBS
UBS analyst Carter Gould raised his price target for Acceleron Pharma to $62 citing the positive results from the Phase 3 Believe study of luspatercept in beta-thalassemia. While not a surprise after the positive Medalist data two weeks ago, a "clear clinical win" was important given a lack of quantitative details in either press release, Gould tells investors in a research note. He keeps a Buy rating on Acceleron.
07/10/18
PIPR
07/10/18
DOWNGRADE
Target $52
PIPR
Neutral
Acceleron downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff downgraded Acceleron Pharma (XLRN) to Neutral and lowered his price target for the shares to $52 from $55. Acceleron and partner Celgene (CELG) last night announced positive Phase III Believe results for luspatercept in transfusion dependent beta thalassemia, Tenthoff tells investors in a research note. The stock in premarket trading is up $6.10, or 13%, to $53.50. This is a nice second win for luspatercept, but Acceleron shares are not a buy at current valuation levels, the analyst contends. He believes luspatercept does not command the same market opportunity in beta thalassemia due to the expected approval of curative gene therapy by 2020. As such, Tenthoff lowered his penetration rates for luspatercept in beta thal to account for gene therapy competition. He says, however, that partner Celgene could acquire Acceleron, which presents a risk to his downgrade.
06/29/18
JPMS
06/29/18
NO CHANGE
Target $54
JPMS
Overweight
Acceleron shares have 30%-35% upside on 'clean win,' says JPMorgan
In a research note partially titled "Gooooal! A Clean Win for MEDALIST Phase 3," JPMorgan analyst Eric Joseph raised his price target for Acceleron Pharma to $54 from $52. While details on specific endpoints were light, the top-line announcement notes highly significant outcomes on both primary and key secondary endpoint, Joseph writes. The analyst views the outcome as a "clean win" that and "materially de-risks" the path forward to approval for luspatercept. He sees 30%-35% upside to current levels for Acceleron shares on higher probability of success assumptions across Street models on myelodysplastic syndromes alone. Joseph keeps an Overweight rating on Acceleron. The stock in premarket trading is up 26.5% to $43.00.
IRBT iRobot
$80.91

0.02 (0.02%)

07/10/18
RAJA
07/10/18
DOWNGRADE
RAJA
Market Perform
iRobot downgraded to Market Perform from Outperform at Raymond James
05/16/18
PIPR
05/16/18
NO CHANGE
Target $78
PIPR
Overweight
iRobot checks show reduced in-stock levels, says Piper Jaffray
Piper Jaffray analyst Troy Jensen says a recent round of channel checks showed iRobot's in-stock levels dropped following Mother's Day weekend sales across U.S. retailers, indicating solid sales volume. The analyst believes the company's Q2 sales will be in-line or potentially above expectations. Further, based on recent patents granted to iRobot, Jensen believes the company's new products in the second half of 2018 will include a new high-end Roomba with an evacuation station to automatically empty the debris bin. He believes this new feature would add "significant value" to the Roomba product. The analyst remains upbeat on iRobot shares with an Overweight rating and $78 price target.
04/19/18
04/19/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Walmart (WMT) upgraded to Buy from Hold at Argus with analyst Christopher Graja saying he believes an improving job market should help low-and-middle-income shoppers spend more. 2. Sprint (S) upgraded to Neutral from Underperform at Macquarie. 3. iRobot (IRBT) upgraded to Overweight from Neutral at Piper Jaffray with analyst Troy Jensen saying tracking data shows iRobot is experiencing "exceptionally strong demand in North America." 4. Diodes (DIOD) upgraded to Buy from Neutral at Longbow with analyst Shawn Harrison saying he expects rising demand, pricing, and Pericom growth to drive sales, gross margins, and earnings higher. 5. Texas Capital (TCBI) upgraded to Overweight from Neutral at Piper Jaffray with analyst Brett Rabatin saying he sees Texas Capital outperforming peers. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/12/18
PIPR
06/12/18
NO CHANGE
Target $78
PIPR
Overweight
iRobot tracking ahead of June quarter expectations, says Piper Jaffray
Mid quarter channel checks indicate iRobot is tracking ahead of expectations for the June quarter and its 2018 guidance will likely "continue to creep higher as the year progresses," Piper Jaffray analyst Troy Jensen tells investors in a research note. The analyst remains upbeat on the shares and would be buyers of the stock at current levels. The robotic vacuum cleaner market has seen U.S. growth accelerate in recent quarters, the analyst adds. He believes this strength will continue throughout the year and expand into other geographies and product segments. Jensen reiterates an Overweight rating on iRobot with a $78 price target.
WHD Cactus
$35.58

1.49 (4.37%)

03/05/18
03/05/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Alta Mesa Resources (AMR) initiated with an Outperform at Imperial Capital. 2. Cactus (WHD) was initiated with an Overweight at Barclays, Piper Jaffray, and JPMorgan, an Outperform at Credit Suisse and a Buy at BofA/Merrill. 3. Victory Capital (VCTR) was initiated with an Overweight at Barclays, Morgan Stanley and JPMorgan, an Outperform at William Blair and RBC Capital, a Market Perform at Keefe Bruyette, a Buy at BofA/Merrill, a Neutral at Goldman Sachs, as well as a Hold at Sandler O'Neill. 4. Evolus (EOLS) was initiated with an Overweight at Cantor Fitzgerald, an Outperform at JMP Securities and a Buy at Mizuho and SunTrust. 5. MacroGenics (MGNX) initiated with a Buy at H.C. Wainwright. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
03/06/18
SBSH
03/06/18
INITIATION
Target $31
SBSH
Buy
Cactus initiated with a Buy at Citi
Citi analyst Scott Gruber started Cactus with a Buy rating and $31 price target. The company is an "emerging leader" within the U.S. onshore wellhead market and stands positioned to deliver "robust" free cash flow for numerous years going forward, the analyst contends.
05/15/18
LEHM
05/15/18
NO CHANGE
Target $36
LEHM
Overweight
Cactus price target raised to $36 from $31 at Barclays
Barclays analyst David Anderson raised his price target for Cactus to $36 saying the company is "hitting on all cylinders." Cactus, after "blowing past expectations" in the quarter, sent "strong signals" that momentum should continue, Anderson tells investors in a research note. He feels this especially true in the Rental business, where the company effectively ran out of equipment to ship to customers causing an acceleration of rental capex this quarter. The analyst keeps an Overweight rating on Cactus shares.
04/06/18
RBCM
04/06/18
INITIATION
Target $32
RBCM
Outperform
Cactus initiated with an Outperform at RBC Capital
RBC Capital analyst Kurt Halead initiated Cactus with an Outperform rating and a price target of $32, saying the stock presents an opportunity for "small cap cyclical growth fund managers looking for direct exposure to the consumable oilfield equipment market and tangential exposure to land drilling and frac". Halead added that the company's free cash flows should allow it to pursue M&A opportunities and also positions it "on the leading edge of product development", translating into market share gains for Cactus.
CELG Celgene
$83.86

1.42 (1.72%)

07/06/18
MSCO
07/06/18
NO CHANGE
MSCO
Morgan Stanley doesn't expect much movement in Celgene on settlement news
Morgan Stanley analyst Matthew Harrison noted that Celgene announced a settlement of ongoing Revlimid patent litigation with Accord Healthcare in the U.K., though he does not expect the stock to move much on this development given that most investors anticipated a generic version of the drug arriving in the EU by the early 2020s. Additionally, he believes investors are more heavily focused on Revlimid's intellectual property situation in the U.S. Harrison maintains his Equal Weight rating and $90 price target on Celgene shares.
06/28/18
PIPR
06/28/18
NO CHANGE
Target $55
PIPR
Overweight
Acceleron price target raised to $55 at Piper Jaffray after luspatercept data
Piper Jaffray analyst Edward Tenthoff raised his price target on Acceleron (XLRN) to $55 and kept his Overweight rating after the company's Phase 3 MEDALIST trial of luspatercept in myelodysplastic syndromes - MDS - met the primary and secondary endpoints. The analyst notes that the company, along with its partner Celgene (CELG) will now report full data at a medical conference this year and then file an NDA and MAA in the first half of next year. Tenthoff adds that today's results increase his confidence for luspatercept in lower-risk, front-line MDS.
06/29/18
JEFF
06/29/18
NO CHANGE
Target $115
JEFF
Buy
Luspatercep data could turn around negative Celgene sentiment, says Jefferies
Last night's positive Phase III data for luspatercep represents a $1B-$2B opportunity and could help turn around negative sentiment on Celgene, Jefferies analyst Michael Yee tells investors in a research note titled "Some Good News Helps Re-instill Some Confidence in Pipeline." The stock is "cheap and assumes nearly no pipeline at current levels," Yee contends. He sees "numerous key catalysts" in the second half of 2018 and keeps a Buy rating on Celgene with a $115 price target.
VVUS VIVUS
$0.75

0.0163 (2.22%)

TODAY'S FREE FLY STORIES

HMNY

Helios and Matheson

$0.02

0.0001 (0.58%)

10:33
10/15/18
10/15
10:33
10/15/18
10:33
Hot Stocks
Helios and Matheson: Proxy firms recommend voting for reverse stock split »

Helios and Matheson…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:30
10/15/18
10/15
10:30
10/15/18
10:30
Conference/Events
RBC Capital healthcare tech analyst to hold analyst/industry conference call »

Healthcare Technology…

PFE

Pfizer

$43.13

-0.65 (-1.48%)

10:30
10/15/18
10/15
10:30
10/15/18
10:30
Options
Pfizer call option buyers as shares slip »

Pfizer call option buyers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 19

    Oct

  • 19

    Oct

  • 22

    Oct

  • 30

    Oct

  • 07

    Nov

10:30
10/15/18
10/15
10:30
10/15/18
10:30
General news
FX Action: USD-CAD »

FX Action: USD-CAD has…

CAMP

CalAmp

$19.42

-0.02 (-0.10%)

, EB

Eventbrite

$27.95

-0.17 (-0.60%)

10:29
10/15/18
10/15
10:29
10/15/18
10:29
Initiation
On The Fly: Top five analyst initiations »

Catch up on today's…

CAMP

CalAmp

$19.42

-0.02 (-0.10%)

EB

Eventbrite

$27.95

-0.17 (-0.60%)

XYF

X Financial

$9.10

-0.45 (-4.71%)

BSVN

Bank7

$18.47

0.35 (1.93%)

ELAN

Elanco

$31.90

-0.76 (-2.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

PH

Parker-Hannifin

$163.81

-3.6 (-2.15%)

, ROK

Rockwell Automation

$170.00

-2.89 (-1.67%)

10:29
10/15/18
10/15
10:29
10/15/18
10:29
Downgrade
On The Fly: Top five analyst downgrades »

Catch up on today's…

PH

Parker-Hannifin

$163.81

-3.6 (-2.15%)

ROK

Rockwell Automation

$170.00

-2.89 (-1.67%)

NTRI

Nutrisystem

$34.46

-2.66 (-7.17%)

KLAC

KLA-Tencor

$91.27

-1.91 (-2.05%)

DLPH

Delphi Technologies

$23.27

-0.09 (-0.39%)

MNST

Monster Beverage

$52.46

-0.83 (-1.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MCD

McDonald's

$164.45

0.63 (0.38%)

, PNC

PNC Financial

$124.75

0.6 (0.48%)

10:29
10/15/18
10/15
10:29
10/15/18
10:29
Upgrade
On The Fly: Top five analyst upgrades »

Catch up on today's…

MCD

McDonald's

$164.45

0.63 (0.38%)

PNC

PNC Financial

$124.75

0.6 (0.48%)

RL

Ralph Lauren

$124.99

3.5 (2.88%)

ATVI

Activision Blizzard

$75.00

-2.99 (-3.83%)

LULU

Lululemon

$144.33

0.63 (0.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 23

    Oct

  • 06

    Nov

  • 16

    Jan

  • 12

    Apr

  • 17

    Jul

  • 16

    Oct

HMLP

Hoegh LNG Partners

$17.82

0.155 (0.88%)

10:29
10/15/18
10/15
10:29
10/15/18
10:29
Hot Stocks
Breaking Hot Stocks news story on Hoegh LNG Partners 

Hoegh LNG trading resumes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMT

Lockheed Martin

$332.99

5.51 (1.68%)

10:26
10/15/18
10/15
10:26
10/15/18
10:26
Periodicals
Lockheed Martin's F-35 flights resume after examination, Reuters reports »

F-35 jets have resumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 30

    Oct

AMZN

Amazon.com

$1,747.72

-40.91 (-2.29%)

10:26
10/15/18
10/15
10:26
10/15/18
10:26
Technical Analysis
Technical Take: Amazon.com poised for a bounce »

The stock was last at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 16

    Oct

  • 17

    Oct

  • 25

    Oct

NBEV

New Age Beverages

$6.62

0.43 (6.95%)

10:25
10/15/18
10/15
10:25
10/15/18
10:25
Options
New Age Beverages call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:25
10/15/18
10/15
10:25
10/15/18
10:25
Conference/Events
Cowen pharmaceuticals analyst to hold an analyst/industry conference call »

Pharmaceuticals Analyst…

IHRT

iHeartMedia

$0.00

(0.00%)

10:25
10/15/18
10/15
10:25
10/15/18
10:25
Conference/Events
Cowen TMT analyst Vitanza to hold an analyst/industry conference call »

Technology, Media and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

PBYI

Puma Biotechnology

$42.19

-0.5 (-1.17%)

, RHHBY

Roche

$0.00

(0.00%)

10:20
10/15/18
10/15
10:20
10/15/18
10:20
Recommendations
Puma Biotechnology, Roche analyst commentary  »

Roche breast cancer data…

PBYI

Puma Biotechnology

$42.19

-0.5 (-1.17%)

RHHBY

Roche

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 19

    Oct

  • 07

    Nov

  • 24

    Dec

10:20
10/15/18
10/15
10:20
10/15/18
10:20
General news
The 0.5% U.S. August business inventory rise »

The 0.5% U.S. August…

10:18
10/15/18
10/15
10:18
10/15/18
10:18
Hot Stocks
Breaking Hot Stocks news story  »

Mercantil Bank Holding…

AAPL

Apple

$218.56

-3.54 (-1.59%)

10:18
10/15/18
10/15
10:18
10/15/18
10:18
Technical Analysis
Technical Take: Apple near session lows »

The stock was last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

10:17
10/15/18
10/15
10:17
10/15/18
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

10:16
10/15/18
10/15
10:16
10/15/18
10:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:15
10/15/18
10/15
10:15
10/15/18
10:15
General news
Treasury Action: yields remained easier »

Treasury Action: yields…

10:13
10/15/18
10/15
10:13
10/15/18
10:13
Hot Stocks
Breaking Hot Stocks news story  »

Mercantil Bank Holding…

ATVI

Activision Blizzard

$74.23

-3.76 (-4.82%)

10:13
10/15/18
10/15
10:13
10/15/18
10:13
Technical Analysis
Technical Take: Activision Blizzard bounces off low of the day »

The shares were last at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HD

Home Depot

$192.26

0.02 (0.01%)

10:10
10/15/18
10/15
10:10
10/15/18
10:10
Options
Home Depot calls active »

Home Depot calls active.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:10
10/15/18
10/15
10:10
10/15/18
10:10
General news
U.S. business inventories rose 0.5% with sales up 0.5% too in August »

U.S. business inventories…

CGC

Canopy Growth

$52.89

3.1 (6.23%)

10:05
10/15/18
10/15
10:05
10/15/18
10:05
Options
Canopy Growth call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.